EWTX — Edgewise Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.68bn
- $1.15bn
- 42
- 29
- 85
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.97 | ||
| Price to Tang. Book | 2.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.89% | ||
| Return on Equity | -24.51% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.
Directors
- Peter Thompson NEC (61)
- Kevin Koch PRE (60)
- Alan Russell CFD (51)
- Badreddin Edris CFD (34)
- R. Michael Carruthers CFO (63)
- John Moore GCN (56)
- Behrad Donovan OTH
- Joanne Donovan OTH (64)
- Laura Brege IND (63)
- Kenneth Harrison IND (40)
- Jonathan Root IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 17th, 2017
- Public Since
- March 26th, 2021
- No. of Shareholders
- 8
- No. of Employees
- 92
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 93,284,528
- Address
- 1715 38Th St, BOULDER, 80301
- Web
- https://edgewisetx.com/
- Phone
- +1 7202627002
- Auditors
- KPMG LLP
Upcoming Events for EWTX
Q3 2024 Edgewise Therapeutics Inc Earnings Release
Similar to EWTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Edgewise Therapeutics share price?
As of Today at 20:25 UTC, shares in Edgewise Therapeutics are trading at $17.05. This share price information is delayed by 15 minutes.
How has the Edgewise Therapeutics share price performed this year?
Shares in Edgewise Therapeutics last closed at $17.05 and the price had moved by +117.75% over the past 365 days. In terms of relative price strength the Edgewise Therapeutics share price has outperformed the S&P500 Index by +73.27% over the past year.
What are the analyst and broker recommendations for Edgewise Therapeutics?
The overall consensus recommendation for Edgewise Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Edgewise Therapeutics dividend yield?
Edgewise Therapeutics does not currently pay a dividend.
Does Edgewise Therapeutics pay a dividend?
Edgewise Therapeutics does not currently pay a dividend.
When does Edgewise Therapeutics next pay dividends?
Edgewise Therapeutics does not currently pay a dividend.
How do I buy Edgewise Therapeutics shares?
To buy shares in Edgewise Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Edgewise Therapeutics?
As of the previous close price of $17.05, shares in Edgewise Therapeutics had a market capitalisation of $1.59bn.
Where are Edgewise Therapeutics shares listed?
Here are the trading details for Edgewise Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: EWTX
What kind of share is Edgewise Therapeutics?
Based on an overall assessment of its quality, value and momentum Edgewise Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Edgewise Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Edgewise Therapeutics is $33.60. That is 97.07% above the last closing price of $17.05.
Analysts covering Edgewise Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.58 for the next financial year.
What is the trend in the Edgewise Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edgewise Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +59.67%.
As of the last closing price of $17.05, shares in Edgewise Therapeutics were trading +34.46% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Edgewise Therapeutics PE Ratio?
The Edgewise Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Edgewise Therapeutics?
Edgewise Therapeutics' management team is headed by:
- Peter Thompson - NEC
- Kevin Koch - PRE
- Alan Russell - CFD
- Badreddin Edris - CFD
- R. Michael Carruthers - CFO
- John Moore - GCN
- Behrad Donovan - OTH
- Joanne Donovan - OTH
- Laura Brege - IND
- Kenneth Harrison - IND
- Jonathan Root - IND